Patents by Inventor Karl Bruce Thor
Karl Bruce Thor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240099998Abstract: Methods, pharmaceutical formulations, and kits are provided for using Transient Receptor Potential Vanilloid 1 (TRPV1) agonists to increase rectal pressure and induce defecation in mammals.Type: ApplicationFiled: January 13, 2022Publication date: March 28, 2024Inventors: Karl Bruce THOR, Lesley MARSON
-
Patent number: 11458112Abstract: Methods, pharmaceutical formulations, and kits are provided for using capsaicin to effectuate voluntary defecation in mammals who cannot defecate without external invasion of the bowel or those who defecate involuntarily (i.e., those having fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing defecation in mammals that do not have defecation dysfunction such as, for example, in a person who is unconscious and may defecate unconsciously or in a pet at a convenient location at a specific time. The methods and compositions provide patients with defecation dysfunction control over when and where they defecate.Type: GrantFiled: January 29, 2020Date of Patent: October 4, 2022Assignee: DIGNIFY THERAPEUTICS, LLCInventors: Karl Bruce Thor, Lesley Marson
-
Patent number: 10994134Abstract: A stimulator device for controlling waste storage for a subject, having one electrode placed in proximity to a portion of each of the right and left pudendal nerves, which contains efferent fibers that, when stimulated, produce contraction of the urethral or anal sphincter. The stimulator device having a pulse generator connected to electrodes, bilaterally, to provide stimulation for each electrode to stimulate pudendal efferent axons. The pulse generator adapted to provide a first type of stimulation to cause waste to be stored within the subject. The pulse generator adapted to provide a second type of stimulation, different from the first type of stimulation, to allow waste to be voided from the subject by blocking nerve impulses that accompany sphincter dyssynergia. An input device to allow an end user to select the first type of stimulation, the second type of stimulation, or no stimulation. Variations of the concept are disclosed.Type: GrantFiled: January 14, 2020Date of Patent: May 4, 2021Assignee: Dignify Therapeutics, LLCInventor: Karl Bruce Thor
-
Publication number: 20210015771Abstract: Methods, pharmaceutical formulations, and kits are provided for using capsaicin to effectuate voluntary defecation in mammals who cannot defecate without external invasion of the bowel or those who defecate involuntarily (i.e., those having fecal incontinence). The pharmaceutical formulations and kits can also be useful for inducing defecation in mammals that do not have defecation dysfunction such as, for example, in a person who is unconscious and may defecate unconsciously or in a pet at a convenient location at a specific time. The methods and compositions provide patients with defecation dysfunction control over when and where they defecate.Type: ApplicationFiled: January 29, 2020Publication date: January 21, 2021Inventors: Karl Bruce THOR, Lesley MARSON
-
Publication number: 20200222693Abstract: A stimulator device for use in controlling waste storage for a patient, the stimulator device having a set of at least one electrode placed in proximity to a relevant portion of a pudendal nerve. The stimulator device having a pulse generator connected to the set of at least one electrode to provide stimulation input for use by the electrode to stimulate the pudendal nerve. The pulse generator adapted to provide a first type of stimulation to cause waste to be stored within the patient. The pulse generator adapted to provide a second type of stimulation different from the first type of stimulation, the second type of stimulation to allow waste to be voided from the patient by blocking nerve impulses that would produce sphincter dyssynergia. An input device to allow an end user to select to apply the first type of stimulation or the second type of stimulation. Variations of the concept are disclosed.Type: ApplicationFiled: January 14, 2020Publication date: July 16, 2020Inventor: Karl Bruce Thor
-
Patent number: 9598434Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.Type: GrantFiled: July 13, 2015Date of Patent: March 21, 2017Assignee: ASTELLAS PHARMA INC.Inventors: Hiroyuki Koshio, Norio Asai, Taisuke Takahashi, Takafumi Shimizu, Yasuhito Nagai, Keiko Kawabata, Karl Bruce Thor
-
Publication number: 20150368220Abstract: [Problem ] To provide a pharmaceutical composition for treating or preventing urinary incontinence on the basis of a novel mechanism of action, and a method for screening a compound to be comprised in the pharmaceutical composition as an active ingredient. [Means for Solution] The present invention relates to a pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, comprising a compound having a melatonin receptor activation action as an active ingredient. Examples of the active ingredient include melatonin, ramelteon, agomelatine, tasimelteon, TIK-301, and the like.Type: ApplicationFiled: July 9, 2013Publication date: December 24, 2015Applicant: Astellas Pharma Inc.Inventors: Toru Watanabe, Keiko Kawabata, Yuka Watanabe, Hironori Yuyama, Noriyuki Masuda, Edward C. Burgard, Karl Bruce Thor
-
Publication number: 20150315208Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.Type: ApplicationFiled: July 13, 2015Publication date: November 5, 2015Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOSHIO, Norio ASAI, Taisuke TAKAHASHI, Takafumi SHIMIZU, Yasuhito NAGAI, Keiko KAWABATA, Karl Bruce THOR
-
Patent number: 9108977Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.Type: GrantFiled: September 13, 2012Date of Patent: August 18, 2015Assignee: ASTELLAS PHARMA INC.Inventors: Hiroyuki Koshio, Norio Asai, Taisuke Takahashi, Takafumi Shimizu, Yasuhito Nagai, Keiko Kawabata, Karl Bruce Thor
-
Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
Publication number: 20140221497Abstract: Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.Type: ApplicationFiled: April 10, 2014Publication date: August 7, 2014Applicant: APBI Holdings, LLC.Inventor: Karl Bruce Thor -
Publication number: 20130059837Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.Type: ApplicationFiled: September 13, 2012Publication date: March 7, 2013Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOSHIO, Norio ASAI, Taisuke TAKAHASHI, Takafumi SHIMIZU, Yasuhito NAGAI, Keiko KAWABATA, Karl Bruce THOR
-
Publication number: 20130012496Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.Type: ApplicationFiled: March 11, 2011Publication date: January 10, 2013Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki Koshio, Norio Asai, Taisuke Takahashi, Takafumi Shimizu, Yasuhito Nagai, Keiko Kawabata, Karl Bruce Thor
-
Publication number: 20110294881Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.Type: ApplicationFiled: August 9, 2011Publication date: December 1, 2011Applicant: EDUSA PHARMACEUTICALS, INC.Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard, Lee R. Brettman, Steven B. Landau, Daniel J. Ricca
-
Publication number: 20110269744Abstract: [Problem] Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. [Means for Solution] The present inventors have investigated compounds having a 5-HT2C receptor agonist activity, which is promising as an active ingredient of a pharmaceutical composition for treating or preventing incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like, and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention.Type: ApplicationFiled: March 9, 2011Publication date: November 3, 2011Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki KOSHIO, Norio ASAI, Taisuke TAKAHASHI, Takafumi SHIMIZU, Yasuhito NAGAI, Keiko KAWABATA, Karl Bruce THOR
-
Publication number: 20110236318Abstract: An animal model of an ejaculation-like reflex, wherein the ejaculation-like reflex is induced by continuous infusion of saline through a catheter extending into the proximal urethra of a non-human male animal, and wherein the urethra of the animal is occluded by extending and bending the penis at the base; and a method of screening a test substance for effectiveness in prevention or treatment of male ejaculatory dysfunction using the animal model.Type: ApplicationFiled: March 23, 2011Publication date: September 29, 2011Applicant: ASTELLAS PHARMA INC.Inventors: Masayuki TANAHASHI, Karl Bruce THOR, Venkateswarlu KARICHETI
-
Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
Patent number: 7718705Abstract: Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.Type: GrantFiled: August 22, 2000Date of Patent: May 18, 2010Assignee: Eli Lilly and CompanyInventor: Karl Bruce Thor -
Publication number: 20090203792Abstract: A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an ?2? subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that interact with the ?2? calcium channel subunit.Type: ApplicationFiled: April 17, 2009Publication date: August 13, 2009Applicant: Dynogen Pharmaceuticals, Inc.Inventors: Karl Bruce Thor, Edward C. Burgard, Mathew Oliver Fraser
-
Patent number: 7459430Abstract: The invention relates to methods of using Cav2.2 subunit calcium channel modulators to treat painful and non-painful lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.Type: GrantFiled: June 8, 2006Date of Patent: December 2, 2008Assignee: Dynogen Pharmaceuticals, Inc.Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard
-
Publication number: 20080275080Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.Type: ApplicationFiled: April 11, 2008Publication date: November 6, 2008Applicant: Dynogen Pharmacueticals, Inc.Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard, Lee R. Brettman, Steven B. Landau, Daniel J. Ricca
-
Patent number: 7223754Abstract: The invention relates to methods of using Cav2.2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat lower urinary tract and related disorders.Type: GrantFiled: November 17, 2004Date of Patent: May 29, 2007Assignee: Dynogen Pharmaceuticals, Inc.Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard